Literature DB >> 12402395

Surgical resection in the treatment of primary gastrointestinal non-Hodgkin's lymphoma: retrospective study.

Ivo Radman1, Jasminka Kovacević-Metelko, Igor Aurer, Damir Nemet, Silva Zupancić-Salek, Vinko Bogdanić, Dubravka Sertić, Mirando Mrsić, Roland Pulanić, Vladimir Gasparović, Boris Labar.   

Abstract

AIM: To evaluate the role of surgical resection in the treatment of patients with primary gastrointestinal non-Hodgkin s lymphoma in our institution.
METHOD: The retrospective study included 79 patients with a histologically confirmed primary gastrointestinal lymphoma, who were diagnosed and treated for the disease in the 1978-1997 period. According to the treatment modality, the patients were divided into surgically treated and surgically non-treated group. Data were analyzed with Fisher s exact test, long-rank test, and Kaplan-Meier method.
RESULTS: The stomach was the primary site of non-Hodgkin s lymphoma in 45 (57%) patients, small intestine in 19 (24%), and colon in 9 (11%) patients. Six patients (8%) had multifocal disease. There were 56 (71%) patients with stages IE and IIE, and 23 (29%) with stages III and IV. Aggressive histology was found in 51 cases (65%), and low grade mucosa-associated lymphoid tissue (MALT) lymphoma in 28 (35%). Helicobacter pylori infection was registered in 20 out of 45 patients with gastric lymphoma. Twenty-six (33%) patients underwent surgical resection followed by chemotherapy, 47 (59%) were treated with chemotherapy alone, and 6 (8%) received antibiotics plus chemotherapy. Fifteen patients needed urgent surgical intervention. The overall response rate was 77%. Complete remission was achieved in 54 (68%) patients and partial remission in 7 (9%). Eighteen patients (23%) experienced progressive disease. A 10-year overall survival (OS) was 63% and event-free survival (EFS) was 52% for all patients. Patients with gastric lymphoma had better OS and EFS than patients with primary lymphoma at other sites (65% vs 42%, and 62 vs 28%, respectively) (p=0.005). A 10-year EFS rates were 58% and 52% for surgically treated and non-treated group, respectively. There was no significant difference between patients with resected and non-resected tumors (p=0.855). Patients with early-stage disease had significantly better OS and PFS than patients with advanced-stage disease (p=0.048).
CONCLUSION: Primary gastrointestinal lymphoma can be successfully treated with chemotherapy alone but surgery remains an important therapeutic option for emergency problems. The main prognostic factors were primary tumor site and extent of the disease.

Entities:  

Mesh:

Year:  2002        PMID: 12402395

Source DB:  PubMed          Journal:  Croat Med J        ISSN: 0353-9504            Impact factor:   1.351


  8 in total

1.  An incidentaloma at ileal intubation.

Authors:  Fergal Donnellan; Sarah Moran; Stephen E Patchett
Journal:  World J Gastrointest Endosc       Date:  2011-11-16

2.  Clinical prognostic analysis of 116 patients with primary intestinal non-Hodgkin lymphoma.

Authors:  Hong-Feng Gou; Jian Zang; Ming Jiang; Yu Yang; Dan Cao; Xin-Chuan Chen
Journal:  Med Oncol       Date:  2010-12-31       Impact factor: 3.064

3.  Role of Surgery in Stages II and III Pediatric Abdominal Non-Hodgkin Lymphoma: A 5-Years Experience.

Authors:  Amany M Ali; Heba A Sayd; Hesham M Hamza; Mohamed A Salem
Journal:  Cancers (Basel)       Date:  2011-03-29       Impact factor: 6.639

4.  B-lymphoblastic lymphoma of the rectum.

Authors:  Puthillathu Unnikrishnan; Geetha Narayanan; Bhavya S Kumar; Nandini Devi
Journal:  Proc (Bayl Univ Med Cent)       Date:  2017-07

5.  Burkitt lymphoma involving jejunum in children.

Authors:  Zhi Li; Jiexiong Feng; Xiaoyi Sun
Journal:  Ann Med Surg (Lond)       Date:  2014-06-26

6.  Synchronous Gastric Carcinoma and Nodal Malignant Lymphoma: A Rare Case Report and Literature Review.

Authors:  Li-Jun Xue; Ji-Hong Yang; Quan-Sheng Su; Hai Wang; Chang Liu
Journal:  Case Rep Oncol       Date:  2010-07-10

7.  R-CHOP with dose-attenuated radiation therapy could induce good prognosis in gastric diffuse large B cell lymphoma.

Authors:  Yuko Mishima; Yasuhito Terui; Masahiro Yokoyama; Noriko Nishimura; Sakura Sakajiri; Kyoko Ueda; Yasutoshi Kuboki; Kenji Nakano; Kazuhito Suzuki; Eriko Nara; Naoko Tsuyama; Kengo Takeuchi; Masahiko Oguchi; Kiyohiko Hatake
Journal:  Exp Hematol Oncol       Date:  2012-09-24

8.  A visual model for prognostic estimation in patients with primary diffuse large B-cell lymphoma of small intestine and colon: analysis of 1,613 cases from the SEER database.

Authors:  Yang Wang; Jia Song; Shupeng Wen; Xiaolan Zhang
Journal:  Transl Cancer Res       Date:  2021-04       Impact factor: 1.241

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.